Accepted medical use

Accepted medical use — formally, currently accepted medical use in treatment in the United States — is a legal criterion established in the Controlled Substances Act of 1970. It is one of several factors the Drug Enforcement Administration weighs when placing a substance in a schedule: alongside abuse potential and abuse liability, the presence or absence of accepted medical use determines which schedule a substance falls into.

The finding is legal in character, not scientific. A substance may have documented therapeutic effects in clinical research, or be in routine prescription use elsewhere in the world, and still fail to satisfy this criterion in the United States.

What it means in practice

Schedule I of the CSA is reserved for substances that carry both a high potential for abuse and no currently accepted medical use. That dual finding means a substance cannot lawfully be prescribed, and researchers wishing to study it must obtain a Schedule I researcher registration — a more demanding process than applies to other scheduled substances.

Whether a substance has accepted medical use is determined through a process involving the DEA and the Department of Health and Human Services. FDA approval of a drug for a specific indication is treated as strong evidence of accepted medical use, but the CSA criterion is a distinct legal finding. Evidence of therapeutic potential — including clinical trial data or investigational designations — does not automatically satisfy it.

How jurisdictions vary

The phrase accepted medical use is specific to United States law. Other systems reach analogous conclusions under different language, and the results do not map directly onto U.S. schedules.

In the United Kingdom, substance classification under the Misuse of Drugs Act 1971 and the right to prescribe are separate questions. A Class A substance can be dispensed under a licence from the Secretary of State, and there is no direct equivalent to the U.S. accepted-medical-use criterion.

International scheduling under the UN conventions — the Single Convention on Narcotic Drugs of 1961 and the Convention on Psychotropic Substances of 1971 — uses its own schedule tiers. A substance's UN schedule does not translate directly to its U.S. schedule number, and member states vary considerably in how they implement treaty obligations.

What is contested

The most contested aspect of this criterion is the gap that can open between a Schedule I 'no currently accepted medical use' finding and the state of the published clinical record. A substance can simultaneously hold a Schedule I placement and formal regulatory designations — from the same federal apparatus — acknowledging preliminary clinical evidence of substantial therapeutic benefit.

These findings are not legally contradictory: the CSA criterion and an investigational designation serve different statutory purposes. The situation illustrates that the phrase 'no currently accepted medical use' functions as a legal conclusion about regulatory approval, not a verdict on the underlying science — a distinction that scheduling disputes have repeatedly turned on.

Scope and currency

This entry is not legal advice and does not describe the law in any specific jurisdiction. Schedules, licensing frameworks, and the legal definition of accepted medical use differ by country and change over time. The per-substance legal status section on each substance page carries its own jurisdiction, date, and source, and is the more reliable value for any specific compound.

This entry states the legal position as of August 2026.